BMJ Open (Sep 2020)

Acceptability and feasibility of two interventions in the MooDFOOD Trial: a food-related depression prevention randomised controlled trial in overweight adults with subsyndromal symptoms of depression

  • Ulrich Hegerl,
  • Edward Watkins,
  • Miquel Roca,
  • Matthew Owens,
  • Mariska Bot,
  • Ingeborg Annemarie Brouwer,
  • Elisabeth Kohls,
  • Brenda Penninx,
  • Gerard van Grootheest,
  • Mieke Cabout,
  • Margalida Gili,
  • Marjolein Visser,
  • Bep Verkerk,
  • Nadine Paans,
  • Carisha Thesing,
  • Deborah Gibson-Smith,
  • Melany Horsfall,
  • Lena Weiss,
  • Amy Romijn,
  • Hannah Bunce,
  • Owain Winfield,
  • Harriet Bunker-Smith,
  • Fern Durbridge,
  • Caterina Versari Molinares,
  • Atikah Sapar,
  • Miquel Tortella,
  • Clara Homar Covas,
  • M Angeles Pérez-Ara,
  • Adoración Castro Gracia,
  • José Luis Reig,
  • Jana Hoesel,
  • Ezgi Dogan,
  • Sabrina Baldofski,
  • Nicole Mauche

DOI
https://doi.org/10.1136/bmjopen-2019-034025
Journal volume & issue
Vol. 10, no. 9

Abstract

Read online

Objectives We report on the acceptability, feasibility, dose-response relationship and adherence of two nutritional strategies to improve mood (multinutrient supplements; food-related behavioural activation (F-BA)) studied in a randomised controlled depression prevention trial (the Multi‐country cOllaborative project on the rOle of Diet, Food‐related behaviour, and Obesity in the prevention of Depression (MooDFOOD) Trial). We also assessed baseline determinants of adherence and assessed whether better adherence resulted in lower depressive symptoms.Design Randomised controlled trial with a 2×2 factorial design conducted between 2015 and 2017.Setting Germany, the Netherlands, UK and Spain.Participants Community sample of 1025 overweight adults with elevated depressive symptoms without a current episode of major depressive disorder. Main eligibility criteria included age (18–75 years), being overweight or obese, and having at least mild depressive symptoms, shown by a Patient Health Questionnaire Score of ≥5. A total of 76% of the sample was retained at the 12-month follow-up.Interventions Daily nutritional supplements versus pill placebo or an F-BA therapy, delivered in individual and group sessions versus no behavioural intervention over a 1-year period.Primary and secondary outcome measures Primary outcome: self-reported acceptability of the interventions. Secondary outcomes: adherence and self-reported depressive symptoms.Results Most participants reported that the F-BA was acceptable (83.61%), feasible to do (65.91%) and would recommend it to a friend (84.57%). Individual F-BA sessions (88.10%) were significantly more often rated as positive than group F-BA sessions (70.17%) and supplements (28.59%). There were statistically significant reductions in depressive symptoms for those who both adhered to the F-BA intervention and had a history of depression (B=−0.08, SE=0.03, p=0.012) versus those who had no history of depression. Supplement intake had no effect on depressive symptoms irrespective of adherence.Conclusions F-BA may have scope for development as a depression prevention intervention and public health strategy but further refinement and testing are needed.Trial registration number NCT02529423.